BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

BIM

115.5

+1.49%↑

SRT3

228.3

-0.7%↓

GXI

55.3

+2.88%↑

ICAD

21.08

-0.57%↓

Search

Sanofi SA

Închisă

SectorSănătate

92.54 -0.88

Rezumat

Modificarea prețului

24h

Curent

Minim

92.18

Maxim

94.26

Indicatori cheie

By Trading Economics

Venit

-2.3B

499M

Vânzări

-6.5B

7.6B

P/E

Medie Sector

20.663

57.333

EPS

1.31

Randament dividend

4.32

Marjă de profit

6.539

Angajați

82,878

EBITDA

-3.7B

563M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+22.28% upside

Dividende

By Dow Jones

Randament dividend

Medie Sector

4.32%

2.63%

Statistici piață

By TradingEconomics

Capitalizare de piață

-20B

111B

Deschiderea anterioară

93.42

Închiderea anterioară

92.54

Scor tehnic

By Trading Central

Încredere

Neutral Evidence

Sanofi SA Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

24 apr. 2025, 08:52 UTC

Câștiguri

Sanofi Sales, Profit Beat Expectations on Higher Demand for Skin, Asthma Drug -- Update

24 apr. 2025, 05:44 UTC

Câștiguri

Sanofi Sales, Profit Beat Expectations

9 apr. 2025, 06:00 UTC

Achiziții, Fuziuni, Preluări

Santander Exploring Options to Sell Polish Unit Stake, Bloomberg Says, Citing Sources

20 mar. 2025, 06:43 UTC

Achiziții, Fuziuni, Preluări

Sanofi to Acquire Autoimmune Disease Treatment From Dren Bio for Up to $1.9 Billion

24 apr. 2025, 12:54 UTC

Market Talk
Câștiguri

Sanofi's Pipeline Updates Seem Mixed -- Market Talk

24 apr. 2025, 10:06 UTC

Market Talk
Câștiguri

Sanofi Starts the Year Strong -- Market Talk

10 apr. 2025, 12:06 UTC

Market Talk
Achiziții, Fuziuni, Preluări

PKO's Hypothetical Acquisition of Santander's Polish Unit Could Increase Its Role in Sector -- Market Talk

10 apr. 2025, 09:10 UTC

Acțiuni populare

Stocks to Watch Thursday: Trump Media, U.S. Steel, Tesla, Barclays -- WSJ

9 apr. 2025, 10:49 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Erste Bank Seen as Potential Buyer for Santander's Polish Unit -- Market Talk

9 apr. 2025, 08:19 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Capital Deployment From Santander's Potential Poland Disposal Is Key Question -- Market Talk

9 apr. 2025, 06:59 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Potential Santander Polish Exit Less Compelling Than Sale of U.K. Bank -- Market Talk

9 apr. 2025, 06:46 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Santander's Potential Polish Operations Disposal Could Free Up Capital to Boost Returns Elsewhere -- Market Talk

4 apr. 2025, 09:07 UTC

Acțiuni populare

Stocks to Watch Friday: Glencore, Apple, Barclays -- WSJ

3 apr. 2025, 07:51 UTC

Market Talk

Big Pharma Stocks Rise After Exclusion From U.S. Tariffs -- Market Talk

2 apr. 2025, 13:44 UTC

Market Talk

Santander Push Into Canada on the Cards -- Market Talk

2 apr. 2025, 09:27 UTC

Acțiuni populare

Stocks to Watch Wednesday: Tesla, Newsmax, Novo Nordisk -- WSJ

26 mar. 2025, 06:19 UTC

Market Talk
Câștiguri

Santander Surpasses 100 Billion-Euro Valuation Milestone -- Market Talk

25 mar. 2025, 10:08 UTC

Market Talk

Santander Needs Step-Up in Profitability to Fully Close Discount -- Market Talk

20 mar. 2025, 09:00 UTC

Top știri

'Anti-Woke' in the U.S., DEI at Home: the New Playbook for European Companies -- WSJ

20 mar. 2025, 06:05 UTC

Achiziții, Fuziuni, Preluări

Sanofi: Deal Seeks to Broaden Immunology Pipeline

20 mar. 2025, 06:05 UTC

Achiziții, Fuziuni, Preluări

Sanofi to Make Potential Future Payments Totaling $1.3B Upon Reaching Milestones

20 mar. 2025, 06:04 UTC

Achiziții, Fuziuni, Preluări

Sanofi to Pay $600M Upfront

20 mar. 2025, 06:02 UTC

Achiziții, Fuziuni, Preluări

Sanofi to Buy Dren Bio's Bispecific Myeloid Cell Engager

20 mar. 2025, 06:00 UTC

Achiziții, Fuziuni, Preluări

Press Release: Sanofi To Acquire Dren Bio's Bispecific Myeloid Cell Engager For Deep B-cell Depletion, Broadening Immunology Pipeline >SAN.FR

18 mar. 2025, 09:33 UTC

Acțiuni populare

Stocks to Watch Tuesday: Nvidia, BYD, Santander, Google -- WSJ

17 mar. 2025, 23:00 UTC

Top știri

Santander Pushes to Expand U.S. Operations by Utilizing Verizon Customer Base -- WSJ

13 mar. 2025, 09:50 UTC

Câștiguri

Santander Approves Final Cash Dividend Per Share of EUR11 cents

13 mar. 2025, 09:49 UTC

Câștiguri

Santander Increased 2024 Cash Payments by 19%

24 feb. 2025, 08:56 UTC

Market Talk
Câștiguri

European Banks' Quarterly Beats Confirm Momentum -- Market Talk

24 feb. 2025, 08:30 UTC

Market Talk
Achiziții, Fuziuni, Preluări

Southern European Banks' Strong Finish to 2024 Confirms Attractiveness -- Market Talk

Comparație

Modificare preț

Sanofi SA Așteptări

Obiectiv de preț

By TipRanks

22.28% sus

Prognoză pe 12 luni

Medie 114.144 EUR  22.28%

Maxim 127 EUR

Minim 83.729 EUR

În baza a 14 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruSanofi SA - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

14 ratings

10

Cumpărare

4

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

91.62 / 93.4Suport & Rezistență

Termen scurt

Neutral Evidence

Termen mediu

Strong Bearish Evidence

Termen lung

Strong Bearish Evidence

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Sanofi SA

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products. In addition, it offers poliomyelitis, pertussis, and hib pediatric vaccines; influenza, booster, meningitis, and travel and endemic vaccines, which includes hepatitis A, typhoid, cholera, yellow fever, and rabies vaccines. The company also provides cough, cold, and flu, allergy, and pain care products, as well as physical, mental, and digestive wellness products; and offers products for itching, hydration, aging, cracking, overnight, and specialty skincare needs like eczema. Further, it has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301, a treatment for alpha-synucleinopathies; Blackstone Life Sciences to develop pivotal studies and clinical development program; and Seagen Inc. to design, develop, and commercialize antibody-drug conjugates for cancer. Additionally, the company has a collaboration agreement with IGM Biosciences, Inc. to develop, manufacture, and commercialize IgM antibody; Skyhawk Therapeutics, Inc to discover and develop novel small molecules; and Adagene Inc., for the discovery and development of antibody-based therapies. It also has collaborations with Scribe Therapeutics Inc. to develop genome editing technologies; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.